Sort
261,768 grants matching “gene therapy”
AI-driven Drug Discovery Targeting Cardiac Fibrosis in Aging Heart
$900,195Joseph C Wu · Stanford University · UG3 · FY2025 · AG
Novel Small Molecules For Acute Liver Failure
$900,132Prakash Narayan · Angion Biomedica Corporation · R44 · FY2007 · AA
Tumor Plasticity
$900,000Dario C. Altieri · Wistar Institute · R35 · FY2017 · CA
EXTRAMULAR RESEARCH FACILITIES CONSTRUCTION
$900,000University Of Florida · C06 · FY2003 · RR
Sterol and Isoprenoid Diseases Consortium
$900,000William B Rizzo · University Of Nebraska Medical Center · U54 · FY2014 · HD
Toward GMP production of antigen specific regulatory T cells
$900,000Guixin Shi · Diagnologix, Llc · R44 · FY2023 · CA
CONTEMPORARY THERAPEUTICS FOR ANAPLASTIC GLIOMAS
$900,000G. Yancey Gillespie · University Of Alabama At Birmingham · P20 · FY2011 · CA
Inherited Neurophathies Consortium (RDCRC)
$900,000Michael E Shy · University Of Iowa · U54 · FY2014 · NS
New classes of optogenetic and chemogenetic tools with a feedback control
$900,000Wenjing Wang · University Of Michigan At Ann Arbor · DP2 · FY2025 · MH
National Coordinating Center (NCC) for the Polycystic Kidney Disease (PKD) Research and Translation Core Centers
$900,000Terry J Watnick · University Of Maryland Baltimore · U24 · FY2020 · DK
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** RECENT FINDINGS FROM OUR ON METRITIS SPONTANEOUS CURE (MSC) USING DEEP ARTIFICIAL NEURAL NETWORKS (ANN) CORRECTLY IDENTIFIED 80% OF THE COWS THAT EXPERIENCED A SPONTANEOUS CURE AND 76% OF ALL COWS THAT CURED OR FAILED TO CURE FROM METRITIS. ALBEIT THESE RESULTS WERE HIGHLY ENCOURAGING, AN EXTERNAL VALIDATION, A COMPREHENSIVE ECONOMIC ANALYSIS, AND AN ASSESSMENT OF OTHER ALREADY COMMERCIALLY AVAILABLE TECHNOLOGIES, SUCH AS COW GENOMICS AND COW SENSOR BEHAVIORAL DATA, WOULD BE CRITICAL TO OPTIMIZE PREDICTIVE MODELS AND SOLIDIFY THE EVIDENCE FOR THE IMPLEMENTATION OF SELECTIVE THERAPY FOR METRITIS AND REDUCE AMU IN DAIRY COWS IN THE VARIOUS DAIRY SCENARIOS. FURTHERMORE, METRITIS IS A POLYMICROBIAL DISEASE IN WHICH COWS FAILING TO CURE METRITIS HAVE AN INCREASED ABUNDANCE OF GENES ASSOCIATED WITH LPS SYNTHESIS (GALE) AND QUORUM SENSING SIGNALING (PGI)THAT MIGHT CONTRIBUTE TO MICROBES INTERACTIONS ASSOCIATED WITH METRITIS CURE FAILURE.THEREFORE, THERE IS A CRITICAL NEED TO EXTERNALLY VALIDATE OUR MSC DEEP ANN PREDICTIVE MODEL'S COST-EFFECTIVENESS AND EVALUATE IF THE INTEGRATION OF MICROBIAL AND HOST GENOMICS AND COW SENSOR BEHAVIORAL DATA CAN IMPROVE MSC PREDICTABILITY AND COST-EFFECTIVENESS. OUR LONG-TERM GOAL IS TO DEVELOP HIGHLY ACCURATE ARTIFICIAL INTELLIGENCE-DRIVEN MODELSTHAT PREDICT METRITIS CURE IN DAIRY COWS IN DIVERSE SCENARIOS AND REDUCE ANTIMICROBIAL USE WITHOUT COMPROMISING ANIMAL WELFARE AND THE COST-EFFECTIVENESS OF DAIRY FARMS. OUR CENTRAL HYPOTHESIS IS THAT THE INTEGRATION OF HOST AND MICROBIAL GENOMICS AND COW'S SENSOR BEHAVIORAL DATA WILL IMPROVE MSC PREDICTABILITY METRITIS AND ALLOW THE DEVELOPMENT OF SELECTIVE THERAPY THAT IS SAFE AND COST-EFFECTIVE IN A VARIETY OF SCENARIOS THAT REPRESENT THE DAIRY LANDSCAPE IN THE US AND BEYOND.
$900,000University Of California, Davis · · FY2024 · National Institute of Food and Agriculture
SPORE in Pancreatic Cancer
$900,000University Of Texas Md Anderson Can Ctr · P20 · FY2003 · CA
SPORE in Pancreatic Cancer
$900,000University Of Alabama At Birmingham · P20 · FY2003 · CA
SPORE in Pancreatic Cancer
$900,000University Of Texas Md Anderson Can Ctr · P20 · FY2004 · CA
The MYC Transcription Factor Network and the Path to Cancer
$899,999Robert Neil Eisenman · Fred Hutchinson Cancer Center · R35 · FY2024 · CA
Targeting undruggable RAS for cancer treatment
$899,999Channing J Der · Univ Of North Carolina Chapel Hill · R35 · FY2022 · CA
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.
$899,988David A Scheinberg · Sloan-Kettering Inst Can Research · R35 · FY2020 · CA
Center for Systems Biology
$899,965John D. Aitchison · Institute For Systems Biology · P50 · FY2011 · GM
Creation of hyperactive transposons for mutagenesis in rodents
$899,865Eric M Ostertag · Transposagen Biopharmaceuticals, Inc. · R44 · FY2011 · RR
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
$899,778Rabi Tawil · University Of Rochester · U01 · FY2019 · NS
Deve inlopment of A High-Throughput Screen for Identification of Targeted Therapies in Brainstem Tumors with the H3K27M Mutation
$899,750David Daniels · Mayo Clinic Rochester · R61 · FY2021 · NS
Anti-Mullerian Inhibiting Substance Type II Receptor (MISIIR) Immunoconjugates to
$899,748Gregory P Adams · Fox Chase Cancer Center · P50 · FY2007 · CA
NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial
$899,746Shalendar Bhasin · Brigham And Women'S Hospital · U01 · FY2022 · AG
UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCY
$899,727Laurence J.n. Cooper · University Of Tx Md Anderson Can Ctr · R33 · FY2010 · CA
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
$899,708William Laurence Dahut · Division Of Clinical Sciences - Nci · ZIA · FY2018 · CA